Palisade Bio, Inc. – NASDAQ:PALI
Palisade Bio stock price today
$0.788
-0.88
-52.81%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Palisade Bio stock price monthly change
-63.22%
month
Palisade Bio stock price quarterly change
-63.22%
quarter
Palisade Bio stock price yearly change
+178.33%
year
Palisade Bio key metrics
Market Cap | 4.89M |
Enterprise value | N/A |
P/E | -0.13 |
EV/Sales | N/A |
EV/EBITDA | 0.49 |
Price/Sales | N/A |
Price/Book | 0.14 |
PEG ratio | N/A |
EPS | -10.41 |
Revenue | N/A |
EBITDA | -14.12M |
Income | -13.48M |
Revenue Q/Q | -100% |
Revenue Y/Y | -200% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePalisade Bio stock price history
Palisade Bio stock forecast
Palisade Bio financial statements
| Jun 2023 | 0 | -3.39M | |
|---|---|---|---|
| Sep 2023 | 0 | -3.59M | |
| Dec 2023 | -250K | -2.97M | 1188.4% |
| Mar 2024 | 0 | -3.52M |
| 2025 | 12.14M | -19.84M | -163.38% |
|---|---|---|---|
| 2026 | 27.87M | -23.62M | -84.77% |
| 2027 | 47.71M | -5.11M | -10.72% |
| 2028 | 48.22K | -11.02M | -22854.17% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 18290000 | 2.49M | 13.61% |
|---|---|---|---|
| Sep 2023 | 17067000 | 2.98M | 17.49% |
| Dec 2023 | 14052000 | 2.73M | 19.49% |
| Mar 2024 | 12652000 | 2.58M | 20.46% |
| Jun 2023 | -2.19M | -4K | 5.30M |
|---|---|---|---|
| Sep 2023 | -2.66M | 0 | 1.57M |
| Dec 2023 | -2.74M | 0 | -134K |
| Mar 2024 | -3.18M | 0 | 2.02M |
Palisade Bio alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 12 |
| Jun 2024 | 9 |
| Jul 2024 | 9 |
Palisade Bio other data
0.59%
-12.20%
of PALI is owned by hedge funds
5.21K
-119.43K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 50000 | 300 |
| May 2024 | 2000 | 0 |
-
What's the price of Palisade Bio stock today?
One share of Palisade Bio stock can currently be purchased for approximately $0.79.
-
When is Palisade Bio's next earnings date?
Unfortunately, Palisade Bio's (PALI) next earnings date is currently unknown.
-
Does Palisade Bio pay dividends?
No, Palisade Bio does not pay dividends.
-
How much money does Palisade Bio make?
Palisade Bio has a market capitalization of 4.89M.
-
What is Palisade Bio's stock symbol?
Palisade Bio, Inc. is traded on the NASDAQ under the ticker symbol "PALI".
-
What is Palisade Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Palisade Bio?
Shares of Palisade Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Palisade Bio have?
As Jul 2024, Palisade Bio employs 9 workers, which is 25% less then previous quarter.
-
When Palisade Bio went public?
Palisade Bio, Inc. is publicly traded company for more then 18 years since IPO on 30 Mar 2007.
-
What is Palisade Bio's official website?
The official website for Palisade Bio is palisadebio.com.
-
Where are Palisade Bio's headquarters?
Palisade Bio is headquartered at 5800 Armada Drive, Carlsbad, CA.
-
How can i contact Palisade Bio?
Palisade Bio's mailing address is 5800 Armada Drive, Carlsbad, CA and company can be reached via phone at 858 704 4900.
Palisade Bio company profile:
Palisade Bio, Inc.
palisadebio.comExchange:
NASDAQ
Full time employees:
9
Industry:
Biotechnology
Sector:
Healthcare
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
5800 Armada Drive
Carlsbad, CA 92008
Carlsbad, CA 92008
CIK: 0001357459
ISIN: US6963892046
CUSIP: 696389105
